Cobenfy — Total Revenues
Bristol-Myers Squibb Cobenfy — Total Revenues increased by 12.0% to $56M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 107.4%, from $27M to $56M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration, strong physician adoption, and effective commercial execution for this specific therapy. A decrease may signal competitive pressure, access challenges, or slower-than-expected patient uptake.
Detailed definition
This metric represents the total net sales generated from the Cobenfy product line, a novel therapeutic treatment within...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or newly launched specialty pharmaceutical products at peer biopharmaceutical companies.
bmy_segment_cobenfy_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $10M | $27M | $35M | $43M | $50M | $56M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | — | +170.0% | +29.6% | +22.9% | +16.3% | +12.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +400.0% | +107.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's cobenfy — total revenues?
- Bristol-Myers Squibb (BMY) reported cobenfy — total revenues of $56M in Q1 2026.
- How has Bristol-Myers Squibb's cobenfy — total revenues changed year-over-year?
- Bristol-Myers Squibb's cobenfy — total revenues increased by 107.4% year-over-year, from $27M to $56M.
- What does cobenfy — total revenues mean?
- Total revenue generated from the sales of the Cobenfy therapeutic product.